Scientists in China have unveiled a breakthrough way to mass-produce powerful cancer-fighting immune cells in the lab. By engineering early-stage stem cells from cord blood—rather than trying to ...
Anyone who has used an induction cooktop to boil noodles is halfway to understanding Mayo Clinic’s new experimental approach to killing cancer cells. The Rochester-based health system announced ...
Optune Pax® with the chemotherapy combination of gemcitabine and nab-paclitaxel is the first treatment to be FDA approved in ...
Dr. Shaun P. McKenzie is board certified in general surgery and in surgical oncology, hepatobiliary surgery, and pancreatic surgery. He is a surgical oncologist with Texas Oncology Surgical ...
Researchers at The University of Texas MD Anderson Cancer Center have developed a new computational approach designed to ...
Distance, lack of coverage, and mistrust have limited Indigenous patients' access to basic and advanced medicine, but cancer centers are embracing strategies to change that.
St. Jude Children’s Research Hospital scientists and multinational collaborators created AI-powered M-PACT to facilitate next ...
Liquid biopsies, which test body fluids that contain cancerous material, including circulating tumor DNA (ctDNA), are a noninvasive way to learn about a cancer's biology.
A new study shows that targeting key epigenetic proteins may permanently switch off cancer genes. Scientists at Monash University, working with Harvard University, report they have found a way to ...
Immunotherapy—which activates the body's own immune system to kill cancer cells—has not worked well against a rare and fatal liver cancer, but a new study finds an existing FDA-approved drug may allow ...
In a significant advancement for thoracic oncology within the Appalachian region, WVU Medicine has announced it is the first health care system in West Virginia to utilize pulsed electric field (PEF) ...
Why most eligible lymphoma patients miss CAR T: experts urge stronger academic-community handoffs, clearer protocols, and ...